Skip to main content
Clinical Trials/JPRN-UMIN000007785
JPRN-UMIN000007785
Recruiting
Phase 2

The efficacy, safety, and the predictive factors of efficacy of low dose Lenalidomide plus Dexamethasone consolidation therapy followed by very low dose Lenalidomide maintenance therapy for multiple myeloma. - The efficacy, safety, and the predictive factors of efficacy of rd therapy

ational Hospital Organization Disaster Medical Center0 sites35 target enrollmentApril 19, 2012

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
multiple myeloma
Sponsor
ational Hospital Organization Disaster Medical Center
Enrollment
35
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 19, 2012
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
ational Hospital Organization Disaster Medical Center

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • The exclusion criteria were a serum creatinine level\>2\.05 mg/dL, liver dysfunction (e.g., a serum total bilirubin level\>2\.0 mg/dL, or serum aspartate/alanine aminotransferase or alkaline phosphatase levels more than 2\.5 times the upper limit of normal), grade 3 or worse peripheral neuropathy, significant comorbidity that would preclude ASCT, poor performance status (\>grade 3\), and a history of any other malignancy with the exception of basal cell carcinoma and stage I cervical cancer.

Outcomes

Primary Outcomes

Not specified

Similar Trials